Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 52.88K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 6.18K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 44.20K shares, a 120.98% increase year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 50.38K shares, a 45.98% decline from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 93.25K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.76M shares, a 447.59% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 103.25K shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 52.88K shares 10-Q · filed 2026-05-08 | 103.25K shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | 6.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 50.38K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 44.20K shares 10-Q · filed 2025-11-06 | 44.09K shares derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | 0.00 shares derived: 10-K 12 month − 3 quarters · filed 2026-03-26 | 19.90K shares derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | 19.90K shares derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -100.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 93.25K shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 20.00K shares 10-Q · filed 2025-11-06 | 20.00K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 0.00 shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-13 | 22.05K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-08 | 1.39M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | 1.41M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 22.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 1.76M shares 10-K · filed 2024-03-26 |
| 2022-09-30 | 1.37M shares 10-Q · filed 2023-11-02 | 2.04M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | 19.32K shares 10-Q · filed 2023-08-08 | 668.77K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 348.55K shares 10-Q · filed 2023-05-04 | 649.45K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | 295.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 321.69K shares 10-K · filed 2023-03-23 |
| 2021-09-30 | 5.00K shares 10-Q · filed 2022-11-14 | |
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-09 | |
| 2021-03-31 | 20.79K shares 10-Q · filed 2022-05-11 | |
| 2020-12-31 | 18.55K shares 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |